ImmuCell Corporation (ICCC)
USD 5.5
(1.66%)
USD 5.5
(1.66%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -5.77 Million USD | -131.54% |
| 2022 | -2.49 Million USD | -3097.44% |
| 2021 | -78 Thousand USD | 92.37% |
| 2020 | -1.02 Million USD | 21.14% |
| 2019 | -1.29 Million USD | 44.19% |
| 2018 | -2.32 Million USD | -1282.14% |
| 2017 | -168 Thousand USD | -133.04% |
| 2016 | 508.44 Thousand USD | -58.09% |
| 2015 | 1.21 Million USD | 825.8% |
| 2014 | -167.15 Thousand USD | -242.39% |
| 2013 | 117.39 Thousand USD | 31.15% |
| 2012 | 89.51 Thousand USD | 121.86% |
| 2011 | -409.51 Thousand USD | -6.45% |
| 2010 | -384.68 Thousand USD | -77.69% |
| 2009 | -216.49 Thousand USD | 53.8% |
| 2008 | -468.55 Thousand USD | -170.76% |
| 2007 | 662.13 Thousand USD | 2.32% |
| 2006 | 647.13 Thousand USD | -8.57% |
| 2005 | 707.78 Thousand USD | 393.16% |
| 2004 | 143.51 Thousand USD | -65.1% |
| 2003 | 411.21 Thousand USD | -53.6% |
| 2002 | 886.23 Thousand USD | 111.01% |
| 2001 | 420 Thousand USD | -81.1% |
| 2000 | 2.22 Million USD | 303.39% |
| 1999 | 550.84 Thousand USD | 650.84% |
| 1998 | -100 Thousand USD | -133.33% |
| 1997 | 300 Thousand USD | 400.0% |
| 1996 | -100 Thousand USD | 0.0% |
| 1995 | - USD | 100.0% |
| 1994 | -100 Thousand USD | 0.0% |
| 1993 | - USD | 100.0% |
| 1992 | -200 Thousand USD | 85.71% |
| 1991 | -1.4 Million USD | -133.33% |
| 1990 | -600 Thousand USD | 40.0% |
| 1989 | -1 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -437.86 Thousand USD | 61.59% |
| 2024 Q2 | -1.53 Million USD | -249.79% |
| 2023 Q3 | -940 Thousand USD | 31.87% |
| 2023 FY | -5.77 Million USD | -131.54% |
| 2023 Q2 | -1.37 Million USD | 40.4% |
| 2023 Q1 | -2.31 Million USD | -38.79% |
| 2023 Q4 | -1.14 Million USD | -21.28% |
| 2022 FY | -2.49 Million USD | -3097.44% |
| 2022 Q4 | -1.66 Million USD | -154.67% |
| 2022 Q1 | 735.66 Thousand USD | 888.45% |
| 2022 Q2 | -684.14 Thousand USD | -193.0% |
| 2022 Q3 | -655 Thousand USD | 4.26% |
| 2021 Q4 | 74.42 Thousand USD | -49.63% |
| 2021 Q3 | 147.76 Thousand USD | 4.71% |
| 2021 Q2 | 141.11 Thousand USD | 131.98% |
| 2021 FY | -78 Thousand USD | 92.37% |
| 2021 Q1 | -441.3 Thousand USD | -333.49% |
| 2020 Q2 | -765.79 Thousand USD | -526.33% |
| 2020 Q4 | 189 Thousand USD | 158.53% |
| 2020 FY | -1.02 Million USD | 21.14% |
| 2020 Q3 | -322.88 Thousand USD | 57.84% |
| 2020 Q1 | -122.26 Thousand USD | 60.56% |
| 2019 Q1 | 144.55 Thousand USD | 113.74% |
| 2019 FY | -1.29 Million USD | 44.19% |
| 2019 Q2 | -627 Thousand USD | -533.74% |
| 2019 Q3 | -502.53 Thousand USD | 19.85% |
| 2019 Q4 | -310 Thousand USD | 38.31% |
| 2018 Q4 | -1.05 Million USD | -320.87% |
| 2018 Q3 | -249.95 Thousand USD | 68.69% |
| 2018 Q2 | -798.36 Thousand USD | -261.05% |
| 2018 Q1 | -221.12 Thousand USD | -13.4% |
| 2018 FY | -2.32 Million USD | -1282.14% |
| 2017 Q1 | 584.24 Thousand USD | 1829.15% |
| 2017 FY | -168 Thousand USD | -133.04% |
| 2017 Q4 | -195 Thousand USD | 42.54% |
| 2017 Q3 | -339.34 Thousand USD | -55.39% |
| 2017 Q2 | -218.38 Thousand USD | -137.38% |
| 2016 Q1 | 452.44 Thousand USD | 56.66% |
| 2016 FY | 508.44 Thousand USD | -58.09% |
| 2016 Q4 | 30.28 Thousand USD | -13.15% |
| 2016 Q3 | 34.87 Thousand USD | 480.88% |
| 2016 Q2 | -9155.00 USD | -102.02% |
| 2015 Q4 | 288.8 Thousand USD | -17.79% |
| 2015 FY | 1.21 Million USD | 825.8% |
| 2015 Q1 | 479.08 Thousand USD | 266.76% |
| 2015 Q3 | 351.29 Thousand USD | 273.48% |
| 2015 Q2 | 94.05 Thousand USD | -80.37% |
| 2014 Q2 | -294.78 Thousand USD | -2110.58% |
| 2014 FY | -167.15 Thousand USD | -242.39% |
| 2014 Q4 | 130.62 Thousand USD | 1164.54% |
| 2014 Q3 | 10.33 Thousand USD | 103.5% |
| 2014 Q1 | -13.33 Thousand USD | 91.15% |
| 2013 Q4 | -150.7 Thousand USD | -362.84% |
| 2013 Q1 | 204.31 Thousand USD | 1311.59% |
| 2013 Q2 | 6452.00 USD | -96.84% |
| 2013 FY | 117.39 Thousand USD | 31.15% |
| 2013 Q3 | 57.33 Thousand USD | 788.65% |
| 2012 FY | 89.51 Thousand USD | 121.86% |
| 2012 Q4 | -16.86 Thousand USD | 73.48% |
| 2012 Q3 | -63.57 Thousand USD | -518.61% |
| 2012 Q2 | 15.18 Thousand USD | -90.19% |
| 2012 Q1 | 154.76 Thousand USD | 29300.19% |
| 2011 Q2 | -258.21 Thousand USD | -1017.2% |
| 2011 Q1 | -23.11 Thousand USD | 81.92% |
| 2011 Q3 | -127.64 Thousand USD | 50.57% |
| 2011 Q4 | -530.00 USD | 99.58% |
| 2011 FY | -409.51 Thousand USD | -6.45% |
| 2010 FY | -384.68 Thousand USD | -77.69% |
| 2010 Q1 | -53.26 Thousand USD | -251.8% |
| 2010 Q2 | -6439.00 USD | 87.91% |
| 2010 Q3 | -197.11 Thousand USD | -2961.28% |
| 2010 Q4 | -127.86 Thousand USD | 35.13% |
| 2009 Q2 | -147.82 Thousand USD | -326.87% |
| 2009 Q1 | -34.62 Thousand USD | 13.4% |
| 2009 Q4 | -15.14 Thousand USD | 19.9% |
| 2009 FY | -216.49 Thousand USD | 53.8% |
| 2009 Q3 | -18.9 Thousand USD | 87.21% |
| 2008 Q3 | -268.44 Thousand USD | -12.89% |
| 2008 Q4 | -39.98 Thousand USD | 85.1% |
| 2008 FY | -468.55 Thousand USD | -170.76% |
| 2008 Q1 | 77.65 Thousand USD | 8.27% |
| 2008 Q2 | -237.78 Thousand USD | -406.19% |
| 2007 Q1 | 296.73 Thousand USD | 91.79% |
| 2007 Q2 | -60.21 Thousand USD | -120.29% |
| 2007 Q4 | 71.72 Thousand USD | -79.73% |
| 2007 Q3 | 353.88 Thousand USD | 687.74% |
| 2007 FY | 662.13 Thousand USD | 2.32% |
| 2006 Q2 | 15.96 Thousand USD | -94.78% |
| 2006 Q4 | 154.71 Thousand USD | -9.46% |
| 2006 Q3 | 170.87 Thousand USD | 970.25% |
| 2006 Q1 | 305.57 Thousand USD | 17.7% |
| 2006 FY | 647.13 Thousand USD | -8.57% |
| 2005 Q3 | 109.43 Thousand USD | 38.1% |
| 2005 Q4 | 259.62 Thousand USD | 137.24% |
| 2005 Q2 | 79.24 Thousand USD | -69.46% |
| 2005 FY | 707.78 Thousand USD | 393.16% |
| 2005 Q1 | 259.47 Thousand USD | 653.04% |
| 2004 FY | 143.51 Thousand USD | -65.1% |
| 2004 Q1 | 172.14 Thousand USD | 234.46% |
| 2004 Q2 | -58 Thousand USD | -133.7% |
| 2004 Q3 | -5074.00 USD | 91.25% |
| 2004 Q4 | 34.45 Thousand USD | 779.09% |
| 2003 Q2 | -124.49 Thousand USD | -117.75% |
| 2003 FY | 411.21 Thousand USD | -53.6% |
| 2003 Q4 | -128.02 Thousand USD | -239.13% |
| 2003 Q3 | -37.75 Thousand USD | 69.68% |
| 2003 Q1 | 701.49 Thousand USD | -1.1% |
| 2002 FY | 886.23 Thousand USD | 111.01% |
| 2002 Q4 | 709.32 Thousand USD | 2227.26% |
| 2002 Q3 | 30.47 Thousand USD | 234.72% |
| 2002 Q2 | -22.62 Thousand USD | -113.38% |
| 2002 Q1 | 169.05 Thousand USD | -33.71% |
| 2001 Q3 | -56.54 Thousand USD | -153.63% |
| 2001 Q4 | 255 Thousand USD | 550.99% |
| 2001 Q2 | 105.43 Thousand USD | -9.19% |
| 2001 Q1 | 116.1 Thousand USD | -94.03% |
| 2001 FY | 420 Thousand USD | -81.1% |
| 2000 FY | 2.22 Million USD | 303.39% |
| 2000 Q4 | 1.94 Million USD | 14518.76% |
| 2000 Q3 | -13.48 Thousand USD | -120.93% |
| 2000 Q2 | 64.43 Thousand USD | -71.62% |
| 2000 Q1 | 227.01 Thousand USD | 50.5% |
| 1999 FY | 550.84 Thousand USD | 650.84% |
| 1999 Q3 | 100 Thousand USD | 0.0% |
| 1999 Q4 | 150.84 Thousand USD | 50.84% |
| 1999 Q1 | 300 Thousand USD | 0.0% |
| 1999 Q2 | 100 Thousand USD | -66.67% |
| 1998 Q1 | 200 Thousand USD | -50.0% |
| 1998 FY | -100 Thousand USD | -133.33% |
| 1998 Q4 | - USD | 100.0% |
| 1998 Q3 | -100 Thousand USD | 0.0% |
| 1998 Q2 | -100 Thousand USD | -150.0% |
| 1997 Q3 | - USD | 100.0% |
| 1997 Q4 | 400 Thousand USD | 0.0% |
| 1997 FY | 300 Thousand USD | 400.0% |
| 1997 Q1 | 200 Thousand USD | 0.0% |
| 1997 Q2 | -200 Thousand USD | -200.0% |
| 1996 FY | -100 Thousand USD | 0.0% |
| 1996 Q4 | 200 Thousand USD | 300.0% |
| 1996 Q3 | -100 Thousand USD | 0.0% |
| 1996 Q2 | -100 Thousand USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1995 FY | - USD | 100.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 Q3 | - USD | 100.0% |
| 1995 Q2 | -100 Thousand USD | -200.0% |
| 1995 Q1 | 100 Thousand USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 FY | -100 Thousand USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 FY | - USD | 100.0% |
| 1992 Q3 | -100 Thousand USD | 0.0% |
| 1992 Q2 | - USD | 100.0% |
| 1992 FY | -200 Thousand USD | 85.71% |
| 1992 Q4 | - USD | 100.0% |
| 1992 Q1 | -100 Thousand USD | 50.0% |
| 1991 Q1 | -400 Thousand USD | -500.0% |
| 1991 FY | -1.4 Million USD | -133.33% |
| 1991 Q4 | -200 Thousand USD | 60.0% |
| 1991 Q3 | -500 Thousand USD | -66.67% |
| 1991 Q2 | -300 Thousand USD | 25.0% |
| 1990 Q1 | -300 Thousand USD | -50.0% |
| 1990 FY | -600 Thousand USD | 40.0% |
| 1990 Q3 | -300 Thousand USD | -200.0% |
| 1990 Q4 | 100 Thousand USD | 133.33% |
| 1990 Q2 | -100 Thousand USD | 66.67% |
| 1989 Q1 | - USD | 0.0% |
| 1989 FY | -1 Million USD | 0.0% |
| 1989 Q3 | -100 Thousand USD | 75.0% |
| 1989 Q4 | -200 Thousand USD | -100.0% |
| 1989 Q2 | -400 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Agenus Inc. | -245.76 Million USD | 97.65% |
| Immix Biopharma, Inc. | -15.42 Million USD | 62.566% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 96.226% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 94.343% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 98.454% |
| MiMedx Group, Inc. | 67.43 Million USD | 108.563% |
| Novavax, Inc. | -545.06 Million USD | 98.941% |
| Seer, Inc. | -86.27 Million USD | 93.307% |
| Acelyrin, Inc. | -381.64 Million USD | 98.487% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 90.724% |
| IO Biotech, Inc. | -86.08 Million USD | 93.292% |
| Ardelyx, Inc. | -66.06 Million USD | 91.259% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 95.642% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 87.053% |
| Fortress Biotech, Inc. | -60.63 Million USD | 90.477% |
| Fortress Biotech, Inc. | -60.63 Million USD | 90.477% |
| Geron Corporation | -184.12 Million USD | 96.864% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 97.187% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 92.922% |
| Incyte Corporation | 597.59 Million USD | 100.966% |
| Innoviva, Inc. | 179.72 Million USD | 103.213% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 32.072% |
| ChromaDex Corporation | -4.93 Million USD | -16.942% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 111.072% |
| MEI Pharma, Inc. | 17.77 Million USD | 132.482% |
| NextCure, Inc. | -62.72 Million USD | 90.793% |
| Onconetix, Inc. | -37.4 Million USD | 84.564% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 85.373% |
| GlycoMimetics, Inc. | -36.89 Million USD | 84.35% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 94.888% |
| Vaxcyte, Inc. | -402.26 Million USD | 98.564% |
| Precigen, Inc. | -95.9 Million USD | 93.979% |
| Pharming Group N.V. | -10.54 Million USD | 45.254% |
| ContextLogic Inc. | -317 Million USD | 98.178% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -60.942% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 92.174% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 76.985% |
| AlloVir, Inc. | -190.41 Million USD | 96.967% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 76.275% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 95.916% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -45939.55% |
| Summit Therapeutics Inc. | -614.92 Million USD | 99.061% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 97.242% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 83.066% |
| Senti Biosciences, Inc. | -92.91 Million USD | 93.785% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 96.775% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 83.567% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 13.619% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 88.712% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 90.21% |
| Chimerix, Inc. | -82.09 Million USD | 92.966% |
| PDS Biotechnology Corporation | -42.94 Million USD | 86.553% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 71.541% |
| CRISPR Therapeutics AG | -153.61 Million USD | 96.241% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 89.959% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 97.136% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 76.472% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 94.116% |
| Precision BioSciences, Inc. | -61.31 Million USD | 90.583% |
| Dyadic International, Inc. | -6.79 Million USD | 15.023% |
| Elevation Oncology, Inc. | -45.7 Million USD | 87.365% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -516.944% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 88.879% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 98.688% |
| Aptorum Group Limited | -2.82 Million USD | -104.436% |
| Bicycle Therapeutics plc | -180.66 Million USD | 96.804% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 55.824% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 82.224% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 69.654% |
| GT Biopharma, Inc. | -7.59 Million USD | 23.988% |
| Alkermes plc | 355.75 Million USD | 101.623% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 91.381% |
| Jaguar Health, Inc. | -41.3 Million USD | 86.018% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 80.333% |
| AbCellera Biologics Inc. | -146.39 Million USD | 96.056% |
| PureTech Health plc | -65.69 Million USD | 91.21% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 68.864% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 97.76% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 84.535% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 92.127% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 76.275% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 91.219% |
| AnaptysBio, Inc. | -163.61 Million USD | 96.471% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 83.875% |
| ESSA Pharma Inc. | -26.58 Million USD | 78.277% |
| Molecular Templates, Inc. | -8.12 Million USD | 28.919% |
| Scopus BioPharma Inc. | -11.6 Million USD | 50.261% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 98.992% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -10042.618% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 88.69% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 78.799% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 90.094% |
| Structure Therapeutics Inc. | -89.62 Million USD | 93.557% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 89.389% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 94.485% |
| Lantern Pharma Inc. | -15.96 Million USD | 63.822% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 79.704% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 42.173% |
| Opthea Limited | -220.24 Million USD | 97.378% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 97.279% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 96.491% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 96.412% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 97.607% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 108.087% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 88.244% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 41.951% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 97.649% |
| Aptose Biosciences Inc. | -51.2 Million USD | 88.723% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 94.125% |
| Soligenix, Inc. | -6.14 Million USD | 5.962% |
| Century Therapeutics, Inc. | -136.67 Million USD | 95.775% |
| Kura Oncology, Inc. | -152.63 Million USD | 96.217% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 93.528% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 45.202% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 1121.203% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -914.868% |
| Autolus Therapeutics plc | -208.38 Million USD | 97.229% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 91.968% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 91.843% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 73.35% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 97.436% |
| GRI Bio, Inc. | -13.03 Million USD | 55.706% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -39.666% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 95.346% |
| IGM Biosciences, Inc. | -246.41 Million USD | 97.657% |
| INmune Bio, Inc. | -30 Million USD | 80.756% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 94.777% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 86.314% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 63.822% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 63.44% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 90.325% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 94.292% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 97.909% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 97.573% |
| Verastem, Inc. | -87.36 Million USD | 93.39% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 89.343% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 96.421% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 95.05% |
| Histogen Inc. | -10.62 Million USD | 45.63% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 59.581% |
| Surrozen, Inc. | -43.04 Million USD | 86.584% |
| Organovo Holdings, Inc. | -14.67 Million USD | 60.639% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -13.516% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 88.967% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 77.142% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 78.563% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 30.902% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 96.178% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 88.197% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 80.573% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 44.569% |
| Apollomics, Inc. | -172.6 Million USD | 96.654% |
| Amarin Corporation plc | -59.11 Million USD | 90.231% |
| Mesoblast Limited | -87.95 Million USD | 93.435% |
| Turnstone Biologics Corp. | -55.2 Million USD | 89.539% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 96.071% |
| Synaptogenix, Inc. | -6.03 Million USD | 4.37% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 64.372% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 92.599% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -20.518% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 31.273% |
| Exelixis, Inc. | 207.76 Million USD | 102.779% |
| Better Therapeutics, Inc. | -39.76 Million USD | 85.476% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 95.988% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 98.908% |
| NLS Pharmaceutics AG | -12.17 Million USD | 52.558% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 25.916% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 81.22% |
| Gritstone bio, Inc. | -138.49 Million USD | 95.83% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 91.042% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -44.367% |
| Avid Bioservices, Inc. | -140.75 Million USD | 95.897% |
| Insmed Incorporated | -749.56 Million USD | 99.23% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 61.983% |
| MediWound Ltd. | -6.71 Million USD | 14.017% |
| OmniAb, Inc. | -50.61 Million USD | 88.592% |
| Alector, Inc. | -130.39 Million USD | 95.571% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 94.922% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 88.862% |
| Zai Lab Limited | -334.62 Million USD | 98.274% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 98.218% |
| Aura Biosciences, Inc. | -76.4 Million USD | 92.442% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 97.539% |
| Immunic, Inc. | -93.61 Million USD | 93.831% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 95.751% |
| Veracyte, Inc. | -74.4 Million USD | 92.239% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 24.766% |
| FibroGen, Inc. | -284.23 Million USD | 97.968% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 77.986% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 17.528% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 69.337% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 101.392% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 74.398% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 111.72% |
| TG Therapeutics, Inc. | 12.67 Million USD | 145.57% |
| Galecto, Inc. | -38.34 Million USD | 84.942% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 69.392% |
| Fortrea Holdings Inc. | -3.4 Million USD | -69.841% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 95.44% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 66.834% |
| XBiotech Inc. | -24.55 Million USD | 76.485% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 91.042% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 90.787% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 94.133% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 73.05% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 89.537% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 99.048% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 91.54% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 97.451% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 74.067% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 97.372% |
| NexImmune, Inc. | -32.34 Million USD | 82.147% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -9.231% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 58.888% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 100.146% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 76.159% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 95.056% |
| Ainos, Inc. | -13.77 Million USD | 58.066% |
| Pluri Inc. | -20.88 Million USD | 72.354% |
| Prothena Corporation plc | -147.02 Million USD | 96.072% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 94.929% |
| Celularity Inc. | -196.29 Million USD | 97.058% |
| Rallybio Corporation | -74.56 Million USD | 92.256% |
| Cue Biopharma, Inc. | -50.73 Million USD | 88.618% |
| MeiraGTx Holdings plc | -84.02 Million USD | 93.128% |
| Omeros Corporation | -117.81 Million USD | 95.099% |
| Humacyte, Inc. | -110.77 Million USD | 94.787% |
| Immunocore Holdings plc | -55.28 Million USD | 89.555% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 67.89% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 74.818% |
| Blueprint Medicines Corporation | -506.98 Million USD | 98.861% |
| CalciMedica, Inc. | -34.35 Million USD | 83.192% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 91.467% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 96.517% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 97.961% |
| Pulmatrix, Inc. | -14.12 Million USD | 59.106% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 83.593% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 93.012% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 98.8% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 94.494% |
| Cytokinetics, Incorporated | -526.24 Million USD | 98.903% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 83.988% |
| Nutriband Inc. | -5.48 Million USD | -5.274% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 85.714% |
| Vor Biopharma Inc. | -117.86 Million USD | 95.101% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 100.133% |
| Evogene Ltd. | -23.87 Million USD | 75.817% |
| ProKidney Corp. | -35.46 Million USD | 83.719% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 95.178% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 26.395% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 99.102% |
| CorMedix Inc. | -46.33 Million USD | 87.538% |
| BioLineRx Ltd. | -60.61 Million USD | 90.473% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 94.324% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 85.938% |
| Atai Life Sciences N.V. | -40.22 Million USD | 85.644% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 92.84% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 92.354% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 98.024% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 79.285% |
| MediciNova, Inc. | -8.57 Million USD | 32.63% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 95.316% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 31.065% |
| GeoVax Labs, Inc. | -25.96 Million USD | 77.762% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 97.586% |
| Biomea Fusion, Inc. | -117.25 Million USD | 95.075% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 99.078% |
| Mereo BioPharma Group plc | -29.46 Million USD | 80.403% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 96.23% |
| Absci Corporation | -110.56 Million USD | 94.777% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 80.847% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 94.273% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 97.552% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 141.001% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 97.007% |
| Allakos Inc. | -185.7 Million USD | 96.89% |
| Imunon, Inc. | -19.51 Million USD | 70.409% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 94.067% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 105.441% |
| BioAtla, Inc. | -123.46 Million USD | 95.323% |
| NLS Pharmaceutics AG | -12.17 Million USD | 52.558% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 64.084% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 98.235% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 84.371% |
| XOMA Corporation | -40.83 Million USD | 85.857% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 94.331% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 95.127% |
| aTyr Pharma, Inc. | -50.38 Million USD | 88.54% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 93.414% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 96.195% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 97.571% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 83.557% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 28.638% |
| Akari Therapeutics, Plc | -10 Million USD | 42.3% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -8477.197% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 102.051% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 13.358% |
| UroGen Pharma Ltd. | -102.24 Million USD | 94.352% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 94.593% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 25.75% |
| Orgenesis Inc. | -55.36 Million USD | 89.569% |
| Entera Bio Ltd. | -8.88 Million USD | 35.037% |
| GH Research PLC | -35.58 Million USD | 83.773% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 72.291% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 92.538% |
| Xencor, Inc. | -126.08 Million USD | 95.42% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -53.347% |
| Replimune Group, Inc. | -215.79 Million USD | 97.324% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 72.847% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 330.155% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 13.358% |
| Portage Biotech Inc. | -75.33 Million USD | 92.335% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 31.065% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 94.026% |
| OncoCyte Corporation | -27.78 Million USD | 79.214% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 56.961% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 48.077% |
| Purple Biotech Ltd. | -19.88 Million USD | 70.953% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 17.729% |
| scPharmaceuticals Inc. | -54.81 Million USD | 89.464% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 67.014% |
| HilleVax, Inc. | -123.56 Million USD | 95.327% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 42.865% |
| Tharimmune, Inc. | -9.31 Million USD | 38.035% |
| Genprex, Inc. | -30.86 Million USD | 81.288% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 97.552% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 80.811% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -224.052% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -9.037% |
| OKYO Pharma Limited | -16.82 Thousand USD | -34220.595% |
| Savara Inc. | -54.69 Million USD | 89.443% |
| Curis, Inc. | -47.41 Million USD | 87.821% |
| Daré Bioscience, Inc. | -30.16 Million USD | 80.854% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 62.612% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | -3.692% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 80.632% |
| BeiGene, Ltd. | -881.7 Million USD | 99.345% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 72.882% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 98.677% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 92.686% |
| Erasca, Inc. | -125.04 Million USD | 95.382% |
| bluebird bio, Inc. | -211.91 Million USD | 97.275% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -15.48% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 103.445% |
| DBV Technologies S.A. | -72.72 Million USD | 92.06% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -15.48% |
| Moderna, Inc. | -4.71 Billion USD | 99.878% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 85.62% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | -1.415% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 90.438% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 94.816% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 95.734% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 87.949% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 95.917% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 96.999% |
| MacroGenics, Inc. | -9.05 Million USD | 36.249% |
| RenovoRx, Inc. | -10.23 Million USD | 43.563% |
| Adicet Bio, Inc. | -142.65 Million USD | 95.952% |
| Prime Medicine, Inc. | -198.13 Million USD | 97.085% |
| Aditxt, Inc. | -32.38 Million USD | 82.167% |
| Adagene Inc. | -18.94 Million USD | 69.521% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 21.023% |
| Quantum-Si incorporated | -95.96 Million USD | 93.982% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 95.149% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 60.388% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 104.364% |
| SciSparc Ltd. | -5.12 Million USD | -12.741% |
| Vericel Corporation | -3.18 Million USD | -81.477% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -4702.001% |
| Minerva Neurosciences, Inc. | -30 Million USD | 80.755% |
| Generation Bio Co. | -126.61 Million USD | 95.439% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 92.078% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 92.996% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 97.797% |
| Invivyd, Inc. | -198.64 Million USD | 97.093% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 98.311% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 33.523% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 125.321% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 41.517% |
| 2seventy bio, Inc. | -217.57 Million USD | 97.346% |
| ADMA Biologics, Inc. | -28.23 Million USD | 79.551% |
| Clene Inc. | -49.5 Million USD | 88.335% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 74.09% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 88.319% |
| GeoVax Labs, Inc. | -25.96 Million USD | 77.762% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 98.24% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 82.255% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 125.416% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 94.155% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 92.275% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 96.409% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 99.061% |
| Evaxion Biotech A/S | -22.12 Million USD | 73.9% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 92.848% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 97.114% |
| Trevena, Inc. | -40.28 Million USD | 85.667% |
| Surrozen, Inc. | -43.04 Million USD | 86.584% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 91.647% |
| Cingulate Inc. | -23.53 Million USD | 75.464% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 16.455% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 85.513% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 25.109% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 93.599% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 90.578% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 90.295% |
| Clearmind Medicine Inc. | -11.95 Million USD | 51.697% |
| Kronos Bio, Inc. | -112.67 Million USD | 94.875% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 91.655% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -227584.319% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 93.277% |
| Statera Biopharma, Inc. | -174.4 Million USD | 96.689% |
| ImmunityBio, Inc. | -583.19 Million USD | 99.01% |
| Korro Bio, Inc. | -81.17 Million USD | 92.886% |
| Kineta, Inc. | -14.09 Million USD | 59.042% |
| BioVie Inc. | -32.12 Million USD | 82.022% |
| Codexis, Inc. | -76.24 Million USD | 92.426% |
| Celularity Inc. | -196.29 Million USD | 97.058% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 97.308% |
| Celcuity Inc. | -63.77 Million USD | 90.946% |
| Virax Biolabs Group Limited | -6.73 Million USD | 14.241% |
| Cibus, Inc. | -267.62 Million USD | 97.842% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 85.68% |
| IN8bio, Inc. | -30 Million USD | 80.756% |
| Kodiak Sciences Inc. | -260.49 Million USD | 97.783% |
| Annexon, Inc. | -134.23 Million USD | 95.698% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 95.071% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 90.569% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 81.694% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 98.423% |
| Eyenovia, Inc. | -27.26 Million USD | 78.817% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 126.745% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -979.364% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 92.442% |
| Arcellx, Inc. | -70.69 Million USD | 91.831% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 86.065% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 95.685% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 80.775% |
| Moolec Science SA | -51.78 Million USD | 88.85% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 88.974% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 86.242% |
| Royalty Pharma plc | 1.13 Billion USD | 100.509% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 95.753% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 35.057% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 72.817% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 96.636% |
| Humacyte, Inc. | -110.77 Million USD | 94.787% |
| 89bio, Inc. | -142.18 Million USD | 95.939% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 91.626% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 44.352% |
| Genelux Corporation | -28.29 Million USD | 79.593% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 80.132% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 96.74% |
| Notable Labs, Ltd. | -11.26 Million USD | 48.734% |
| Liquidia Corporation | -78.5 Million USD | 92.644% |
| Mustang Bio, Inc. | -51.6 Million USD | 88.809% |
| Immunovant, Inc. | -259.33 Million USD | 97.773% |
| Quantum-Si incorporated | -95.96 Million USD | 93.982% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 92.073% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 70.205% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 93.984% |
| Acasti Pharma Inc. | -12.85 Million USD | 55.072% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 74.287% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 63.822% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 96.834% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -34.246% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 53.692% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 80.419% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 85.189% |
| PepGen Inc. | -78.62 Million USD | 92.656% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 80.602% |
| United Therapeutics Corporation | 984.8 Million USD | 100.586% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 74.058% |
| Solid Biosciences Inc. | -96.01 Million USD | 93.986% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -20.518% |
| Immuneering Corporation | -53.47 Million USD | 89.201% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -13.516% |
| Silo Pharma, Inc. | -3.7 Million USD | -56.041% |
| Belite Bio, Inc | -31.63 Million USD | 81.744% |
| XOMA Corporation | -40.83 Million USD | 85.857% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 89.378% |
| Bionomics Limited | -15.49 Billion USD | 99.963% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 93.124% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 80.195% |
| uniQure N.V. | -308.47 Million USD | 98.128% |
| Cassava Sciences, Inc. | -97.21 Million USD | 94.06% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 21.023% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 95.322% |
| Forte Biosciences, Inc. | -31.47 Million USD | 81.654% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 29.593% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 80.134% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -979.364% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 77.986% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 64.971% |
| Altimmune, Inc. | -88.44 Million USD | 93.471% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 96.19% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 80.195% |
| Compugen Ltd. | -18.75 Million USD | 69.209% |
| Peak Bio, Inc. | -1259.26 USD | -458470.748% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 87.46% |
| Benitec Biopharma Inc. | -21.75 Million USD | 73.451% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 98.296% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 93.039% |
| Zura Bio Limited | -60.36 Million USD | 90.433% |
| PolyPid Ltd. | -23.86 Million USD | 75.803% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 63.294% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 93.039% |
| Instil Bio, Inc. | -156.08 Million USD | 96.3% |
| argenx SE | -295.05 Million USD | 98.043% |
| Immunome, Inc. | -106.8 Million USD | 94.593% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 86.411% |
| Verona Pharma plc | -54.36 Million USD | 89.379% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 94.221% |
| Shattuck Labs, Inc. | -87.29 Million USD | 93.385% |
| CervoMed Inc. | -2.17 Million USD | -165.881% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 95.367% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 56.634% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 86.742% |
| Moolec Science SA | -51.78 Million USD | 88.85% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -33295.143% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 95.726% |
| Design Therapeutics, Inc. | -66.86 Million USD | 91.363% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 92.907% |
| NeurAxis, Inc. | -14.62 Million USD | 60.52% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 84.756% |
| Lumos Pharma, Inc. | -34.03 Million USD | 83.033% |
| Achilles Therapeutics plc | -69.66 Million USD | 91.711% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 94.221% |
| 180 Life Sciences Corp. | -19.93 Million USD | 71.033% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 291.924% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -227584.319% |
| Nutriband Inc. | -5.48 Million USD | -5.274% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 94.265% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 88.12% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 92.509% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 83.001% |
| MoonLake Immunotherapeutics | -36 Million USD | 83.963% |
| Palisade Bio, Inc. | -12.3 Million USD | 53.052% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 86.291% |
| Beam Therapeutics Inc. | -132.52 Million USD | 95.643% |
| Neurogene Inc. | -36.31 Million USD | 84.099% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 96.466% |
| AEON Biopharma, Inc. | -52.55 Million USD | 89.012% |
| Sesen Bio, Inc. | -19.88 Million USD | 70.959% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 91.933% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 53.855% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 98.7% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 94.824% |
| Athira Pharma, Inc. | -117.67 Million USD | 95.093% |
| Vaccinex, Inc. | -20.25 Million USD | 71.485% |
| HCW Biologics Inc. | -24.99 Million USD | 76.896% |
| XOMA Corporation | -40.83 Million USD | 85.857% |
| Nektar Therapeutics | -276.05 Million USD | 97.908% |
| Arvinas, Inc. | -367.3 Million USD | 98.428% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -8477.197% |
| Merus N.V. | -154.93 Million USD | 96.273% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 94.073% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 81.601% |
| Rezolute, Inc. | -68.45 Million USD | 91.565% |
| Clene Inc. | -49.5 Million USD | 88.335% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 62.56% |
| BeyondSpring Inc. | -21.02 Million USD | 72.536% |
| Synlogic, Inc. | -57.28 Million USD | 89.919% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 51.478% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 46.66% |
| Peak Bio, Inc. | -1259.26 USD | -458470.748% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 84.547% |
| Krystal Biotech, Inc. | 10.93 Million USD | 152.823% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 95.965% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 98.224% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -25.019% |
| MannKind Corporation | -11.93 Million USD | 51.628% |
| Ikena Oncology, Inc. | -68.16 Million USD | 91.529% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 72.522% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 93.786% |
| Gossamer Bio, Inc. | -179.81 Million USD | 96.789% |
| CohBar, Inc. | -11.96 Million USD | 51.726% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 77.607% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 80.847% |
| Legend Biotech Corporation | -518.25 Million USD | 98.886% |
| Mural Oncology plc | -207.44 Million USD | 97.216% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 95.347% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 68.427% |
| Disc Medicine, Inc. | -76.42 Million USD | 92.444% |
| Champions Oncology, Inc. | -7.27 Million USD | 20.635% |
| REGENXBIO Inc. | -263.49 Million USD | 97.808% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 45.59% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 87.844% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 84.797% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 94.235% |
| Vaxart, Inc. | -82.46 Million USD | 92.998% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 1830.149% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 84.619% |
| Cellectis S.A. | -101.05 Million USD | 94.286% |
| Longeveron Inc. | -21.41 Million USD | 73.032% |
| Repare Therapeutics Inc. | -93.79 Million USD | 93.843% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 98.923% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 91.886% |
| Revolution Medicines, Inc. | -436.36 Million USD | 98.677% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 12.12% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 81.266% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 91.671% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 91.079% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 41.142% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 100.16% |
| Denali Therapeutics Inc. | -145.22 Million USD | 96.024% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -4702.001% |
| Veru Inc. | -93.15 Million USD | 93.801% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 78.636% |
| Cingulate Inc. | -23.53 Million USD | 75.464% |
| Passage Bio, Inc. | -102.06 Million USD | 94.342% |
| Context Therapeutics Inc. | -23.96 Million USD | 75.903% |
| Exicure, Inc. | -16.91 Million USD | 65.859% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 96.943% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 84.709% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 11.26% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 96.873% |
| Nuvalent, Inc. | -126.21 Million USD | 95.425% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 45.086% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 93.353% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 81.094% |
| OmniAb, Inc. | -50.61 Million USD | 88.592% |
| Anew Medical, Inc. | 1.34 Million USD | 528.979% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 64.01% |
| Lipocine Inc. | -16.35 Million USD | 64.686% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 91.303% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 90.931% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 86.314% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 87.961% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 70.881% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 98.934% |
| Ocugen, Inc. | -63.07 Million USD | 90.845% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 93.968% |
| Q32 Bio Inc. | -112.96 Million USD | 94.888% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 66.411% |
| Alumis Inc. Common Stock | -154.99 Million USD | 96.274% |
| Equillium, Inc. | -13.33 Million USD | 56.696% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 90.434% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 27.708% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 69.368% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 90.226% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 94.958% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 68.579% |
| Dominari Holdings Inc. | -22.88 Million USD | 74.764% |
| Edesa Biotech, Inc. | -8.37 Million USD | 31.045% |
| vTv Therapeutics Inc. | -20.25 Million USD | 71.483% |
| Bio-Techne Corporation | 168.1 Million USD | 103.435% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 98.36% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 104.482% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 95.26% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 84.779% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 94.873% |
| Nkarta, Inc. | -117.5 Million USD | 95.085% |
| BioCardia, Inc. | -11.57 Million USD | 50.094% |
| Iterum Therapeutics plc | -38.37 Million USD | 84.951% |